ESPR – esperion therapeutics, inc. (US:NASDAQ)

News

Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes
Why The Narrative Around Esperion Therapeutics Is Shifting After Analyst Upgrades And Trial Results [Yahoo! Finance]
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion Therapeutics (NASDAQ:ESPR) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
Esperion Therapeutics (NASDAQ:ESPR) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $9.00 price target on the stock.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com